- Open Access
Homology modeling and docking studies of ENPP4: a BCG activated tumoricidal macrophage protein
- Dongmei Yan†1,
- Weiwei Han†2,
- Zehua Dong3,
- Qihui Liu1,
- Zheng Jin1,
- Dong Chu1,
- Yuan Tian1,
- Jinpei Zhang1,
- Dandan Song1,
- Dunhuang Wang1 and
- Xun Zhu1Email author
© Yan et al. 2016
- Received: 6 October 2015
- Accepted: 21 January 2016
- Published: 28 January 2016
The 3D structure and functions of ENPP4, a protein expressed on the surface of Bacillus Calmette–Guerin (BCG)-activated macrophages, are unknown. In this study, we analyzed the 3D structure of ENPP4 and determined its tumoricidal effects on MCA207 cells.
Homology modeling showed that Arg305, Tyr341, Asn291, and Asn295 are important residues in substrate, adenosine triphosphate (ATP), binding. A molecular dynamics study was also carried out to study the stability of ENPP4 (including zinc atoms) as well as its ligand–enzyme complex. BCG increased ENPP4 expression in macrophages, and specific blocking of ENPP4 in BCG-activated macrophages (BAMs) significantly reduced their cytotoxicity against MCA207 cells.
These results indicate that zinc remains inside the ENPP4 protein, a BCG activated tumoricidal macrophage protein, throughout the simulation. Important information for the design of new inhibitors was obtained.
- ENPP4 protein
- Homology modeling
- Molecular docking
- Anti-tumor activity
Macrophages are the first line of defense of the human body against cancer development. Bacillus Calmette–Guerin (BCG) is a highly effective mediator that initiates the tumoricidal effect of macrophages through direct contact [1–5]. However, the mechanism of the antitumor effects of BCG remains unknown.
BCG can bind with TLR2 and TLR4 and upregulate certain proteins expressed on the macrophage surface or secreted to the microenvironment . Activated macrophages can secrete large amounts of pro-inflammatory cytokines, such as tumor necrosis factor-α(TNF-α) and interlukine-12(IL-12), Nitric oxide(NO), reactive oxygen intermediates and highly express MHC-II and the costimulatory molecules CD80 and CD86 . These molecules contribute to the tumoricidal effects of macrophages. Aside from these molecules , other membrane proteins involved in anti-tumor activities have been found to exist on the surface of BCG-activated macrophage (BAMs), as proven by the LS-LSM/MS technique.
Ectonucleotide pyrophosphatase–phosphodiesterases 4 (ENPP4) is an upregulated protein expressed on the BAM surface [2, 3]. However, its functions are incompletely understood. The nucleotide pyrophosphatase–phosphodiesterase or ectonucleotide pyrophosphatase–phosphodiesterase family includes eight members (NPP1–NPP8 or ENPP1–ENPP8) [9–11]. ENPP1–ENPP3 are composed of two N-terminal somatomedin B (SMB)-like domains (SMB1 and SMB2), a catalytic domain, and a nuclease-like domain (ENPP3 is monomeric). These phosphodiesterases are type-2 transmembrane metalloenzymes and have a short intracellular N-terminus, a single transmembrane region, and an extracellular domain that contains a catalytic site. By contrast, members ENPP4–ENPP7 consist of a single catalytic domain. Isoforms ENPP4 and ENPP5 are type-1 transmembrane proteins with a short intracellular C-terminus and a small extracellular region that contains only a phosphodiesterase motif.
The related physiological and pathological roles of ENPP family members, including their regulation of extracellular pyrophosphate levels, cell motility, migration, angiogenesis, and tumor cell invasion, have recently become the focus of intensive research [12–15]. The isozyme ENPP1 catalyzes nucleotides that generate pyrophosphate, which can prevent excessive bone calcification. The subtype ENPP2 (or autotaxin) hydrolyzes lysophosphatidylcholine into lysophosphatidic acid and is involved in vasculature and neural tube formation and lymphocyte migration . The enzyme ENPP3 (CD203) is a basophile marker  with a glycosylated type II transmembrane structure. ENPP5 has not been widely studied, but its closely related molecule, ENPP2, has been widely implicated in neoplasia and extensively studied in efforts to develop small-molecule inhibitors . In fact, ENPP2 has been identified as a novel angiogenesis-associated gene . The isoform ENPP6 has lysophospholipase-C activity for choline-containing glycerophosphodiesters, and the isoform NPP7 has alkaline sphingomyelinase activity and catalyzes lysophosphatidylcholine. No study on the structure and functions of ENPP8 has yet been reported. Although some studies have reported the structure of ENPP4, its 3D structure and related functions are largely unknown.
The present study aims to analyze the 3D structure of ENPP4 on the BAM surface through molecular modeling and study its tissue distribution and tumoricidal effects through immunohistochemistry.
The 3D models validation with Procheck, and Errat
Ramachandran plot: 84.3 % core 13.4 % allow 1.3 % gener
ENPP1 (PDB Id 4GTX)
88.7 % core 11.3 % allow 0.0 % gener
All of these findings indicate that the 3D structure of ENPP4 obtained by MD simulation is reasonable and can be used for further investigations.
ENPP family proteins are membrane-bound glycoproteins. ENPP1 has been reported to cause human diseases characterized by ectopic calcification . ENPP2 is a secreted lysophospholipase D that hydrolyzes lysophosphatidylcholine to produce lysophosphatidic acid (LPA), which, in turn, activates G protein-coupled receptors to evoke various cellular responses . The five other mammalian ENPP proteins, ENPP3–ENPP7, have distinct substrate specificities and tissue distributions and thus participate in different biological processes. However, the 3D structure and biological functions of ENPP4 remain unknown.
ENPP1–ENPP3 are composed of two N-terminal SMB-like domains (SMB1 and SMB2), a catalytic domain, and a nuclease-like domain, whereas ENPP4–ENPP7 consist of a catalytic domain and lack the SMB-like and nuclease-like domains . To determine the binding site between the protein and the substrate, the cavity volume was estimated by CASTp as a function of the radius of the probe sphere. A probe radius of 1.4 A outlined a cavity of 2237.4 Å3 for ENPP4 (Additional file 2: Figure S2A) and a cavity of 1177.7 Å3 for ENPP1 (Additional file 2: Figure S2B). The active pockets of ENPP4 and the template were similar. The active residues in ENPP1 were Asp358, His362, His517, Asp200, Thr238, Asp405, and His406. In ENPP4, Asp192, His196, His339 Asp37, Thr73, Asp240, and His241 were located in the catalytic domain. The reconstructed structure of ENPP4 reveals that the insertion loop (residues 139–158) participates in the formation of the substrate-binding pocket. In particular, M155 and S158 are located on the protein surface, whereas P140 and W138 are located at the bottom of the active pocket. The different binding pockets observed may influence the substrate specificities of the two proteins.
Construction of pET-28a–ENPP4 and expression of recombined ENPP4 protein and its polyantibody
Expression of ENPP4 in tissues
Tumoricidal activity of ENPP4 in BAMs
MD simulation was employed to assess the stability of the homology model and the ligand–enzyme complex. In the homology model, we focused on the catalytic site, particularly on the amino acids that coordinate Zn2+ and the interactions between the metal and the enzyme. MD simulation was used to analyze the ENPP4–ATP complex and identify the possible bioactive conformation of the molecule. The conformation of ATP obtained from molecular docking and the ENPP4 model were used as the starting point for the simulation. The ligand was mainly stabilized by the hydrogen bonds determined during our MD simulation. Among Arg305, Tyr341, Asn291, and Asn295, only Tyr431 was conserved in the ENPP4 family. These observations suggest that this specific residue is necessary for the molecular evolution of the ENPP family. The plot shows the distance between the H in the oxygen of Tyr341 and ATP. Interestingly, the stable formation of a hydrogen bond between the ligand and Asp141 was observed during the 10 ns MD simulation. This finding suggests that the residue of the catalytic site can stabilize interactions between OH and ATP; however, other studies featuring longer simulations are necessary to support this idea.
Mycobacterium bovis BCG is the most widely used vaccine in the world. BCG generates a local immunological reaction that activates immune cells, including polymorphonuclear and mononuclear cells, in bladder tumors after BCG therapy . The ENPP family has been reported to be involved in various pathologies, including tumor progression and inflammation. ENPP2 is a secreted lysophospholipase D that generates the lipid mediator LPA, a mitogen, and a known chemoattractant for many cell types . We have certified that the expression of ENPP4 is upregulated by BCG (Additonal file 3: Figure S3). Blocking ENPP4 on BAM significantly downregulates the anti-tumor activity of the cell, which demonstrates that ENPP4 has potential tumoricidal activity.
ENPP4 showed a catalytic domain in Asp192, His196, His339 Asp37, Thr73, Asp240, and His241, which suggests that the ENPP4 may affect some receptor such as ATP receptor or insulin receptor on the surface of tumor cells to reduce their proliferation by indirectly or directly contact, receptively [19, 20]. On the one hand, ENPP4 may catalize the extracellular ATP released from tumor cells and reduce the binding between ATP and ATP receptor [19, 21], on the other hand, ENPP4 may contact the insulin receptor and inhibit the insulin receptor activity [20, 22].
Altergether, ENPP4 may thus be targeted as a therapeutic molecule for treating tumors. To explore the therapeutic potential of such a strategy, more detailed knowledge of the functions of ENPP4 and its ligand in tumor cells is needed.
Our findings provide novel insights into the structure of ENPP4 and help researchers better understand its diverse cellular functions.
All experiments conform to Jilin University guidelines on the ethical use of animals and were approved by the Institutional Animal Care and Use Committee. The mice used were C57BL/6 (wild-type, WT).
The amino acid sequence of the target protein, ENPP4, was obtained from the National Center for Biotechnology Information NCBI (http://0-www.ncbi.nlm.nih.gov.brum.beds.ac.uk/) (GenBank: NP_950181; template protein: ENPP1 (PDB Id 4GTX) . The BLAST search algorithm was used for an online search (http://www.ncbi.nlm.nih.gov). A modeler module was employed to build the 3D structure of the protein. Modeling was then carried out using Gromacs 4.5.1 software  with the Gromos53a6 all-atom force field. The temperatures were kept constant at T = 25 °C by coupling to a Berendsen thermostat with a coupling time of T = 0.1 ps. The protein was solvated using a box of TIP3P  water molecules extending at least 10 Å away from the boundary of any protein atom with an integration step of 2 fs. Non-bonded interactions were calculated using a cutoff of 10 Å. Long-range electrostatic interactions were calculated by Particle–Mesh Ewald summation with a grid spacing of 1.2 Å and cubic interpolation. After 1000 steps of steepest descent energy minimization, the solvent and ions were equilibrated by 0.5 ns molecular dynamics (MD) simulation, with the heavy protein atoms subjected to harmonic constraints under a force constant of k = 1000 kcal/(mol−1 · nm−2). Finally, a production run was carried out for 10 ns, and the coordinates of all atoms at each picosecond were stored for further analysis. In our studies, CASTp (http://cast.engr.uic.edu/cast/)  was used to identify all of the cavities associated with the model and the template and measure their volumes. The results obtained were further used for protein-ligand docking investigations.
The software AutoDock Vina [26, 27] was applied for docking studies. The 3D structures of the substrate were downloaded from the Chemspider database. The target used in our study was the 3D structure of ENPP4. The grid size for docking measured 36 × 36 × 36 Å3.
Cloning of ENPP4 gene in the expression vector pET-28a
To obtain a mouse peritoneal macrophage cell preparation, female C57BL/6 mice, 10 week of age, were immunized intraperitoneally (i.p.) with 4 mg of BCG (Chengdu Institute of Biological Products) three times on days 2, 10, and 12. Three days after the last i.p. injection, the mice were sacrificed and peritoneal cells were collected. Adherent macrophages were collected to prepare the total RNA and cDNA of ENPP4 by RT-PCR [2, 3]. Briefly, PCR reactions were performed using self-designed primer pairs: EF (5’-CGGGAATTCTCAGCACCTCGGTTACTT-3’) and ER (5’-AAACTCGAGAAGAATCGCAGCCACAGG-3’). All amplification reactions consisted of an initial denaturation step at 94 °C for 5 min, 30 cycles of 94 °C denaturation for 1 min, 57 °C annealing for 1 min, and 72 °C extension for 2 min, followed by a final extension at 72 °C for 10 min using 2 units of Taq DNA polymerase. The cDNA of ENPP4 was then cloned to pET-28a to obtain the pET-28a–ENPP4 plasmid.
Expression and purification of recombinant ENPP4 protein in Escherichia coli
To determine the expression of the recombinant ENPP4 protein, Escherichia coli Rosetta (DE3) (Invitrogen) transformed with pET-28a–ENPP4 plasmid DNA was inoculated in a tube containing 10 mL of LB medium supplemented with kanamycin and chloromycetin. The tube was allowed to culture overnight at 37 °C in a shaking incubator (180 rpm) until the culture reached an OD of 0.6 when read at a wavelength of 600 nm. Protein expression was induced by the addition of 0.2, 0.4, 0.6, and 0.8 mM isopropyl βD-1-thiogalactopyranoside. After 6 h of induction at 37 °C, the cells were collected by centrifugation for sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).
To obtain the recombinant ENPP4 protein, bacterial cells were harvested by centrifugation at 4 °C and resuspended in PBS buffer. The bacterial pellets were then mixed with 10 mmol/L MgSO4, 0.01 mg/mL DNaseI, and 0.1 mg/mL lysis enzyme and left at 4 °C for 20 min. After centrifugation, the bacterial pellets were loaded with ice-cold lysis buffer (50 mmol/L Tris-Cl, 0.1 mol/L NaCl, 5 mmol/L EDTA, 0.1 % NaN3, 0.5 % Triton X-100, pH 6.8) and sonicated at 1000 W for 5 s with 10 s intervals for 160 cycles. The supernatant was discarded, and the pellet (inclusion bodies) containing the recombinant ENPP4 protein was subjected to dilute renaturation and dialysis renaturation and concentration. The purity of the extracted protein was detected by SDS-PAGE.
Preparation of polyclonal antibodies and Western blot analysis
Purified recombitant protein was used as the immunogen. Approximately 100 μg of the fusion protein emulsified in complete Freund’s adjuvant was administered during initial inoculation, and 50 μg of fusion protein emulsified in incomplete Freund’s adjuvant was given after 2 weeks. This procedure was repeated 5 times at 1 week intervals. Final rabbit serum was harvested after immunization.
ENPP4 peptides were separated by SDS-PAGE and electrotransferred onto the PVDF membrane. The membrane was blocked with 3 % bovine serum albumin in PBS for 2 h at room temperature. Subsequently, anti-ENPP4 antibodies were added at a dilution of 1:1000 and incubated at room temperature for 1 h. After washing thrice for 15 min, IgG goat-anti-rabbit-HRP was added and incubated for 1 h at room temperature. After a final washing, the resulting signals were detected using DAB (3,3-diaminobenzidine tetrahydrochloride).
Immunohistochemistry for ENPP4 detection in mouse tissues
Various mouse tissues (including heart, liver, kidney, spleen, muscle, lung, intestine, uterus, and ovary) were formalin-fixed at 4 °C overnight and then embedded in paraffin and sectioned for histology. Immunohistochemical staining of serial sections was performed to detect the expression and distribution of ENPP4. All samples were incubated in 0.3 % H2O2 for 10 min at room temperature to inactivate endogenous peroxidase. The paraffinized sections were then incubated with anti-ENPP4 primary antibody for 1 h at room temperature. After washing, the sections were incubated with peroxidase-conjugated goat anti rabbit IgG for 40 min. After a final washing, the resulting signals were detected using DAB and photographed with a microscope.
Tumoricidal effect of ENPP4 on MCA207 cells
BAM-mediated tumor cytotoxicity was determined with and without anti-ENPP4 antibodies. Peritoneal macrophages were harvested from mice and fixed with 1 % paraformaldehyde for 30 min at room temperature. Afterward, 6 × 105 cells were incubated for 2 h with 5 μL of anti-ENPP4 serum (previously prepared by our research group) and 5 μL of control serum (from preimmunized rabbit). The blocked cells were then washed twice with RPMI 1640 medium, seeded into a 96-well flat-bottom plate containing 1 × 104 MCA207 target cells/well, and incubated for 48 h. The number of viable tumor cells was determined by MTT (5 mg/mL, Sigma) assay. The absorbance at 570 nm was recorded directly using a microplate reader (Model 550, Bio-RAD).
Purified ENPP4 protein (prepared by our team) was added to MCA207 (1 × 104 cells, cultured in 96-well plates) at concentrations of 1, 10, 20, and 40 μg/mL, and the cells were incubated for 48 h at 37 °C under a 5 % CO2 atmosphere. The proliferation levels of MCA207 were detected by MTT assay.
Each experiment was repeated at least three times. Data were expressed as mean ± SEM and analyzed by one-way analysis of variance. P values < 0.05 (95 % confidence level) were considered statistically significant.
This work was funded by a grant from the National Program On Key Basic Research Project (973 Program No. 2012CB721003) and National Natural Science Foundation of China(81571530).
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Quiding-Järbrink M, Raghavan S, Sundquist M. Enhanced M1 macrophage polarization in human helicobacter pylori-associated atrophic gastritis and in vaccinated mice. PLoS One. 2010;5(11):e15018.PubMedPubMed CentralView ArticleGoogle Scholar
- Tsung K, Dolan JP, Tsung YL, Norton JA. Macrophages as effector cells in interleukin 12-induced T cell-dependent tumor rejection. Cancer Res. 2002;62(17):5069–75.PubMedGoogle Scholar
- Zhang L, Lun Y, Yan D, Yu L, Ma W, Du B, et al. Proteomic analysis of macrophages: A new way to identify novel cell-surface antigens. J Immunol Methods. 2007;321(1–2):80–5.PubMedView ArticleGoogle Scholar
- Liu X, Dowell AC, Patel P, Viney RP, Foster MC, Porfiri E, et al. Cytokines as effectors and predictors of responses in the treatment of bladder cancer by bacillus Calmette-Guérin. Future Oncol. 2014;10(8):1443–56.PubMedView ArticleGoogle Scholar
- Lodillinsky C, Langle Y, Guionet A, Góngora A, Baldi A, Sandes EO, et al. Bacillus calmette guerin induces fibroblast activation both directly and through Macrophages in a mouse bladder cancer model. PLoS One. 2010;5(10):e13571.PubMedPubMed CentralView ArticleGoogle Scholar
- Arko-Mensah J, Julián E, Singh M, Fernández C. TLR2 but not TLR4 signalling is critically involved in the inhibition of IFN-gamma-induced killing of mycobacteria by murine macrophages. Scand J Immunol. 2007;65(2):148–57.PubMedView ArticleGoogle Scholar
- Sica A, Invernizzi P, Mantovani A. Macrophage plas- ticity and polarization in liver homeostasis and pathology. Hepatology. 2014;59(5):2034–42.PubMedView ArticleGoogle Scholar
- Zhang L, Zhu H, Lun Y, Yan D, Yu L, Du B, et al. Proteomic analysis of macrophages: a potential way to identify novel proteins associated with activation of macrophages for tumor cell killing. Cell Mol Immunol. 2007;4(5):359–67.PubMedGoogle Scholar
- Nowak-Machen M, Lange M, Exley M, Wu S, Usheva A, Robson SC. Lysophosphatidic acid generation by pulmonary NKT cell ENPP-2/autotaxin exacerbates hyperoxic lung injury. Purinergic Signal. 2015;11(4):455–61.PubMedView ArticleGoogle Scholar
- Nakanaga K, Hama K, Aoki J. Autotaxin: an LPA producing enzyme with diverse functions. J Biochem. 2010;148(1):13–24.PubMedView ArticleGoogle Scholar
- Hausmann J, Perrakis A, Moolenaar WH. Structure–function relationships of autotaxin, a secreted lysophospholipase D. Adv Biol Regul. 2013;53(1):112–7.PubMedView ArticleGoogle Scholar
- Cheng HY, Dong A, Panchatcharam M, Mueller P, Yang F, Li Z, et al. Lysophosphatidic acid signaling protects pulmonary vasculature from hypoxia-induced remodeling. Arterioscler Thromb Vasc Biol. 2012;32(1):24–32.PubMedPubMed CentralView ArticleGoogle Scholar
- Thiel A, Kesselring R, Pries R, Wittkopf N, Puzik A, Wollenberg B. Plasmacytoid dendritic cell subpopulations in head and neck squamous cell carcinoma. Oncol Rep. 2011;26(3):615–20.PubMedGoogle Scholar
- Liu S, Murph M, Panupinthu N, Mills GB. ATX-LPA receptor axis in inflammation and cancer. Cell Cycle. 2009;8(22):3695–701.PubMedPubMed CentralView ArticleGoogle Scholar
- Smith SJ, Tilly H, Ward JH, Macarthur DC, Lowe J, Coyle B, et al. CD105 (Endoglin) exerts prognostic effects via its role in the microvascular niche of paediatric high grade glioma. Acta Neuropathol. 2012;124(1):99–110.PubMedPubMed CentralView ArticleGoogle Scholar
- Kato K, Nishimasu H, Okudaira S, Mihara E, Ishitani R, Takagi J, et al. Crystal structure of Enpp1, an extracellular glycoprotein involved in bone mineralization and insulin signaling. Proc Natl Acad Sci U S A. 2012;109(42):16876–81.PubMedPubMed CentralView ArticleGoogle Scholar
- Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K, et al. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol. 2002;158:227–33.PubMedPubMed CentralView ArticleGoogle Scholar
- Hausmann J, Kamtekar S, Christodoulou E, Day JE, Wu T, Fulkerson Z, et al. Structural basis of substrate discrimination and integrin binding by autotaxin. Nat Struct Mol Biol. 2011;18(2):198–204.PubMedPubMed CentralView ArticleGoogle Scholar
- Chin CN, Dallas-Yang Q, Liu F, Ho T, Ellsworth K, Fischer P, et al. Evidence that inhibition of insulin receptor signaling activity by PC-1/ENPP1 is dependent on its enzyme activity. Eur J Pharmacol. 2009;606(1–3):17–24.PubMedView ArticleGoogle Scholar
- Salisbury TB, Tomblin JK. Insulin/Insulin-like growth factors in cancer: new roles for the aryl hydrocarbon receptor, tumor resistance mechanisms, and new blocking strategies. Front Endocrinol (Lausanne). 2015;6:12.Google Scholar
- Giannuzzo A, Pedersen SF, Novak I. The P2X7 receptor regulates cell survival, migration and invasion of pancreatic ductal adenocarcinoma cells. Mol Cancer. 2015;14(1):203.PubMedPubMed CentralView ArticleGoogle Scholar
- Gallagher EJ, Alikhani N, Tobin-Hess A, Blank J, Buffin NJ, Zelenko Z, et al. Insulin receptor phosphorylation by endogenous insulin or the insulin analog AspB10 promotes mammary tumor growth independent of the IGF-I receptor. Diabetes. 2013;62(10):3553–60.PubMedPubMed CentralView ArticleGoogle Scholar
- Gruber CC, Pleiss J. Systematic benchmarking of large molecular dynamics simulations employing GROMACS on massive multiprocessing facilities. J Comput Chem. 2011;32(4):600–6.PubMedView ArticleGoogle Scholar
- Jorgensen WL, Chandrasekhar J, Madurs J, Impey RW, Klein ML. Comparison of simple potential functions for simulating liquid water. J Chem Phys. 1983;79:926–35.View ArticleGoogle Scholar
- Dundas J, Zheng O, Tseng J, Binkowski A, Turpaz Y, Liang Y. CASTp: computed atlas of surface topography of proteins with structural and topographical mapping of functionally annotated residues. Nucleic Acids Res. 2006;34:W116–8.PubMedPubMed CentralView ArticleGoogle Scholar
- Seeliger D, de Groot BL. Ligand docking and binding site analysis with PyMOL and Autodock/Vina. J Comput Aided Mol Des. 2010;24(5):417–22.PubMedPubMed CentralView ArticleGoogle Scholar
- Trott O, Olson A. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455–61.PubMedPubMed CentralGoogle Scholar